Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of D064 and D702 Combination in Essential Hypertension
NCT06121518Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telmisartan and Levamlodipine in essential hypertension (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jul 2023; status: completed.
02
Drugs
telmisartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06121518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121518.